PHYLOGICAPLATFORMSCOMBININGTOPROGRESSCOMMERCIALISATION

AGM25 November 2016

Ms StephanieUnwin

Chair

For

per

sona

l use

onl

y

DisclaimerThe purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC)[‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain mayrequire further explanation and/or clarification. Accordingly, these slides and the information they containshould be read in conjunction with past and future announcements made by Phylogica and should not be reliedupon as an independent source of information. Please contact Phylogica and/or refer to the Company's websitefor further information.

The views expressed in this presentation contain information derived from publicly available sources that havenot been independently verified. No representation or warranty is made as to the accuracy, completeness orreliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number ofassumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about futureevents are subject to risks, uncertainties and other factors, many of which are outside Phylogica’s control.Important factors that could cause actual results to differ materially from assumptions or expectationsexpressed or implied in this presentation include known and unknown risks. Because actual results could differmaterially to assumptions made and Phylogica’s current intentions, plans, expectations and beliefs about thefuture, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Phylogica. Nothing in thispresentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares inany jurisdiction.

2

For

per

sona

l use

onl

y

2016AYEAROFSTRONGPROGRESS

FurthervalidationofourFPPintracellulardeliverytechnologyplatform

§ FPP-mediateddeliveryofproteincargoesisveryrapidandefficient

§ Quantifiedapproximateconcentrationoftheproteindeliveredintothecell

– farsuperiorconcentrations(witharangeofnewcargoes)tothoseachievablewithanextensivelyvalidatedconventionalcellpenetratingpeptide(TAT)

FPPisconsistentlyproducingbetterresultsversusthegoldstandardFor

per

sona

l use

onl

y

Progressontheinternaldiscoveryprogram

IdentifiedPhylomers foruseasthedrugcargoitself

§ Internal iMYC cancer program continues to build an impressive proof of concept datapack on the way to formal preclinical development in the second half of 2017

§ Narrowed the number of proprietary iMYC candidates to five and the most suitableleads will be chosen for optimisation

For

per

sona

l use

onl

y

iMYC candidates

§ Performing well on a number of measures

§ No evidence of FPP-mediated toxicity

§ Improvements in pharmacokinetics

§ Evidence of activity in two independent animal models of cancer even whenadministered intravenously

For

per

sona

l use

onl

y

BuildingconfidenceintheiMYCprogram

§ The iMYC program is our most advanced with entry into a formal pre-clinical programplanned for H2 2017

§ Phylogica is planning to achieve substantial increases in the potency of both its leadFPP and its lead iMYC before further multi-parameter optimisation of the conjugatebegins

For

per

sona

l use

onl

y

ProgressonCollaborations

§ Since June we have signed three non-disclosure agreements with internationalpharmaceutical companies to discuss elements of Phylogica’s technology portfolio.

§ Genentech are due to make a decision regarding licensing/extension of novelantimicrobials research program in December 2016

§ Phylogica’s delivery technology (in the form of its FPPs) is being examined by multiplethird parties (Academic, Biotech and Pharma) for the delivery of various proprietarydrug cargoes

For

per

sona

l use

onl

y

Phylomer Platform

§ The core intellectual property of Phylogica is our extensive library made up of proteinfragments expressed from the genetic material of micro-organisms (Phylomers)

§ For several years, our team of scientists, managers and advisers has been workinghard to utilise our Phylomer library to discover more efficient peptides to deliver arange of biologics cargoes into the inside of cells

For

per

sona

l use

onl

y

Platformcontinued

§ Phylogica has significantly expanded the landscape of druggable targets as well asenhancing the specificity and sensitivity of these drug-target interactions

§ Searching through our extensive library to identify Phylomers that may be used asthe drug cargo in conjunction with the Functional Penetrating Phylomers (FPPs) led toour iMYC program

For

per

sona

l use

onl

y

2016summary

§ Shortlisted oncology drug candidates for lead optimisation

– Potential for formal pre-clinical studies in second half of 2017

§ FPP cell delivery system is showing excellent results and remains highlycompetitive

– See the next presentation from Paul Watt, our Chief Scientific Advisor

Wethankallofourhardworkingscientificteamandourloyalshareholdersfortheirsupport,asPhylogicagetsclosertoreachingcommercialoutcomesfrom

itsexceptionalPhylomerlibrary

For

per

sona

l use

onl

y

TechnologyOverviewandUpdate

Adjunct ProfessorPaulWatt

ChiefScientificAdvisor

For

per

sona

l use

onl

y

Phylogica ValueCreationEngines

12

§ Discovery (Phylomers)

§ Delivery (FPPs)

§ Development (iMYCs)

For

per

sona

l use

onl

y

DELIVERY:

FunctionalPenetratingPhylomers “FPPs”

13

For

per

sona

l use

onl

y

Biologicsdrugsaretrappedwithinendosomesandthustheirtherapeuticeffectsareconstrained

Drug

Drug

Drug

Contacttriggersformationofendosomes

99.9%ofdrugtrappedinendosome

CellMembrane

CellMembrane

Endosome

Drugcontactscellmembrane

Buddingendosome

BIOLOGICS?

BIOLOGICS?

SmallMoleculeDrugs(10%)Undruggedtargets(90%)

80%ofpotentialdrugtargetsareinsidecells

For

per

sona

l use

onl

y

BiotinTag

EscapedPhylomer+Cargo

PYC’sEndosomalEscapeTrapAssayidentifiesPhylomers thatcanliberatecargoesOUTofendosome

Phylomer Phylomer

TrappedPhylomer+Cargo

§ RarePhylomers identifiedthatcandelivercargoesintocellsandthenliberatecargoesfromtheendosomearecalled‘FPPs’

Avitag

Enzymaticattachment

ReleaseandCapture(StreptavidinBeads)

Phylomer

Streptavin

For

per

sona

l use

onl

y

Phylomer FPPscandeliveradiverserangeofbiologicscargoesintocells

Peptides

Toxins

Scaffolds

Enzymes

✔

✔

✔

✔

✔Oligonucleotides

FPP

For

per

sona

l use

onl

y

17

§ ExamplesofcargoesdeliveredwithFPP01oritsderivatives§ FPPversatileenoughtodelivermultiplecargoeswithdiversesizeandcharges

CargoClass Cargo Size/Charge IC50* **MED

Toxin/largeprotein Bouganin 28-50kDa,pI 7.8(different constructs)

20nM ND

Smallproteinscaffold

Omomyc 11kDa,pI 9.6 700nM-5µM

ND

Enzymatic protein 𝛽-lactamase 42KDa, pI 5.5 ND ND

Largedisorderedprotein

PAS 50kDaMW,600kDaequiv.hydrodynamicradius,pI 5.9

ND 5µM

Peptide Apoptotic(PAP)PPIinhibitor(DPMI⍺)Splitproteincomplementation(S11ofGFP)Bcl-2familyinhibitorypeptides–26aa

17aa,pI 10.715aa,pI 8.2630aa,pI 6.75

26aa,pI 6.28

1.7µM8µM

ND

1.6µM

1.25µM

1.25µM

Bispecifics Bcl-2inhibitory peptide+Omomycscaffold

37kDa,pI 8.02 190nM 156nM

Oligonucleotides Exon-skippingMorpholinos 24base pairs,neutral ND 50nM

*IC50s tested in various cell lines **Minimal Effective Dose ND - Not determined (only tested when relevant)

Phylomer FPPscandeliveradiverserangeofbiologicscargoesintocells- continued

For

per

sona

l use

onl

y

FurtherevidenceforsuperiordeliveryofFPPvs.TAT:quantifieddeliveryoflarger(iMyc)cargoes

18

§ TwodistinctFPP-iMyc fusionproteinsappliedtomammaliancellsfor60min§ Assaythatspecificallyquantifiestheefficiencyofcellentry&escapeofiMyc from

theendosometothecytoplasm§ FPPsagainshowvastlysuperioruptakeandendosomalescapecomparedtothe

conventionalCPPTAT,particularlyatlowerconcentrations

0

5000

10000

15000

20000

25000

30000

35000

FPP_01.1 TAT

Alpha&signal&(A.U)

iMyc&0177&Endosomal&Release:&FPP_01.1&versus&Tat&

16uM4uM2uM

0

5000

10000

15000

20000

25000

30000

FPP_01.1 TAT

Alpha&signal&(A.U)

iMyc&0113&Endosomal&Release:&FPP_01.1&versus&Tat&

16uM4uM2uM

FPP conjugates of iMyc cargoes (0113 and 0177) show greater endosomal release than equivalent Tat conjugates at all concentrations tested

For

per

sona

l use

onl

y

19

Groups (8 mice per group) 1)  2x105 cells/mouse 2)  2x104 cells/mouse 3)  2x103 cells/mouse 4)  Naive

EuMyc cells/mouse (in 100uL PBS)

D0 D9

Weigh&prior&to&start&of&exp&

At each time point: -  2 mice per group are

culled and weighed -  Spleens (and weigh)

and bone marrow collected for FACS

D7 D5 D3 D4D6D8

Miceinjecteddailywith40nanomoles ofPhylomer FPP-Omomyc fusionfor4days

EvidenceofefficacyfollowingintravenousdeliveryinEµMyc lymphomamodel

*Limitedto4dailyinjectionsduetopreviousanimalethicsconstraints.Potentialtoincreasedosenumbersinfutureexperiments.

§ 4daily*injectionsofFPP-Omomyc reducedgrowthoflymphomacellsinspleen§ AlsosawareductioninlymphomacellsinthebonemarrowwithFPP-Omomyc injections§ FPP-Omomyc demonstratesefficacyfollowingIVinjection,priortoanyoptimisation

Mock FPP-OmomycSaline C27_Omyc_V5

0.0

0.2

0.4

0.6

0.8

1.0

% T

umou

r bur

den

Spleen D7 - 2.5x105 EµMyc cells

*

Saline C27_Omyc_V5 Omyc0.0

0.2

0.4

0.6

0.8

1.0

% T

umou

r bur

den

Spleen D7 - 5x105 EµMyc cells

*

**

Mock FPP-Omomyc

Extractspleencellsatday7(6mice/cohort)MeasurelabelledEmMyc lymphomacellsbyflowcytometry

For

per

sona

l use

onl

y

20 20

§ Enables endosomal escape

§ Compatible with wide range of cargoes

§ Outperforms other intracellular delivery technologies

§ Functional in multiple cell types

§ Viable manufacturing and strong IP Position

§ Better understanding of mechanism of action

§ Preliminary evidence of in vivo efficacy

§ Promising initial safety signals

FPPs– Whatwehavenowestablished

FurthervalidationofFPPPlatformisgeneratingincreasedexternalinterestFor

per

sona

l use

onl

y

iMYC Program

(FPPcombinedwithiMYC cargo)

21

For

per

sona

l use

onl

y

iMYC ProgramDevelopmentTimelines

22

For

per

sona

l use

onl

y

Goodprogresswithproof-of-conceptdiscoveryprogram

23

For

per

sona

l use

onl

y

SUMMARY

24

For

per

sona

l use

onl

y

Multiplecommercialisation opportunitiesforFPPs

25

FunctionalPenetratingPhylomers

Improvedeliveryofexistingornewdrugs

‘ValueAdding’

Platform Products

Fullyintegrateddrugdelivery/discoveryplatform

‘PhylomerTherapeutics’

Commercial&AcademicCollaborations

iMYC,STAT5&YB1programs

For

per

sona

l use

onl

y

Commercialisation Progress

§ Academic and Commercial Collaborations progressing

– Murdoch University – Oligonucleotides for Muscular Dystrophy

– ONJCRI (formerly Ludwig Institute) – Myc and Bcl2/Mcl1 Bispecifics

– Genentech – Next generation Antimicrobials

– >5 active other (confidential) collaborations

– 5 new NDAs with Pharma/Biotech signed since end of Q1, 2016

§ iMYC program

– Early engagement underway with pharma/biotech

– On track for formal preclinical in 2H17 – next value milestone

§ Phylomer Libraries

– Phoremost target and small molecule discovery alliance

– Potential to generate novel targets and new chemistry

26

For

per

sona

l use

onl

y

ThankstoourtalentedR&Dteamfortheirhardworkandtoourshareholdersforsupport

27

• Katrin Hoffmann,DRSO• Heique Bogdawa• NadiaMilech• KarenKroeger• PaulaCunningham• Tatjana Heinrich• MariaKerfoot• Emanuela Ferrari• FerrerOng• BrookeLongville• ScottWinslow• Danie Champain• TracyChai• SuzyJuraja• MarkAnastasas• Renae Barr

• LauraFlorez• RobDewhurst• MarieScobie• RichardFrancis• LeanneNeville• JasminHeng

For

per

sona

l use

onl

y